ophthalmologyОфтальмологияOphthalmology in Russia1816-50952500-0845Ophthalmology10.18008/1816-5095-2014-2-10-18ophthalmology-19Research ArticleОБЗОРЫREVIEWSОбзор топических форм антимикробных препаратов, применяемых в офтальмологииTopical antimicrobial agents in ophthalmology. A reviewДовганьЕ. В.Dovgan’E. V.

отделение клинической фармакокинетики

office of clinical pharmacokinetics

dovganrus@mail.ruАНО Институт клинической фармакологии ОГБУЗ Смоленская областная клиническая больницаРоссияInstitute of clinical pharmacology Smolensk regional clinical hospitalRussian Federation2014080720141121018Copyright © Довгань Е.В., 20142014Довгань Е.В.Dovgan’ E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ophthalmojournal.com/opht/article/view/19

Обзор представляет сведения о различных группах антимикробных препаратов — фторхинолонов, аминогликозидов, макролидов, фузидовой кислоты, хлорамфеникола — их эффективности в отношении разнообразных микроорганизмов. Проанализированы данные, полученные различными исследователями. Особенное внимание уделено вопросу антибиотикорезистентности возбудителей инфекций в офтальмологии, подробно описана фармакокинетика топических антимикробных препаратов, применяемых в офтальмологии, их безопасность, переносимость. Представлены одобренные в РФ показания к применению топических АМП в офтальмологии. Сделан вывод о том, что с учетом фармакокинетических и фармакодинамических характеристик, благоприятного профиля безопасности и хорошей переносимости, следует признать, что именно фторхинолоны являются препаратами выбора для эмпирической антимикробной терапии инфекций в офтальмологии.

The data on different antimicrobial agents (fluoroquinolones, minoglycosides, macrolides, fusidic acid, chloramphenicol) and their activity against various microorganisms are reviewed. The findings from different researchers are analyzed. Considerable attention is devoted to the problem of antimicrobial resistance in ophthalmology. Pharmacokinetics of topical antimicrobial agents applied in ophthalmology, their safety and tolerability are described. The indications for topical antimicrobial agents use in ophthalmology approved in Russian Federation are presented. With regard for pharmacokinetics and pharmacodynamics, safety profile and good tolerability, it is concluded that fluoroquinolones are medication of choice for empirical antimicrobial treatment in ophthalmology.

антимикробные препараты в офтальмологииантибиотикорезистентностьпоказанияфторхинолоны.antimicrobial medications in ophthalmologyantimicrobial resistanceindicationsfluoroquinolones.ReferencesSnyder RW, Glasser DB. Antibiotic therapy for ocular infection. West J Med 1994; 161:579‑584.Snyder RW, Glasser DB. Antibiotic therapy for ocular infection. West J Med 1994; 161:579‑584.Sharma S. Diagnosis of infectious diseases of the eye. Eye (Lond) 2012; 26:177‑184.Sharma S. Diagnosis of infectious diseases of the eye. Eye (Lond) 2012; 26:177‑184.Pearlman E, Sun Y, Roy S, Karmakar M, Hise AG, Szczotka-Flynn L, et al. Host defense at the ocular surface. Int Rev Immunol 2013; 32:4‑18.Pearlman E, Sun Y, Roy S, Karmakar M, Hise AG, Szczotka-Flynn L, et al. Host defense at the ocular surface. Int Rev Immunol 2013; 32:4‑18.Bremond-Gignac D, Mariani-Kurkdjian P, Beresniak A, El Fekih L, Bhagat Y, Pouliquen P, et al. Efficacy and safety of azithromycin 1.5 % eye drops for purulent bacterial conjunctivitis in pediatric patients. Pediatr Infect Dis J; 2010;29:222‑226.Bremond-Gignac D, Mariani-Kurkdjian P, Beresniak A, El Fekih L, Bhagat Y, Pouliquen P, et al. Efficacy and safety of azithromycin 1.5 % eye drops for purulent bacterial conjunctivitis in pediatric patients. Pediatr Infect Dis J; 2010;29:222‑226.Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT. A phase III clinical trial of 0.5 % levofloxacin ophthalmic solution versus 0.3 % ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003; 110:457‑465.Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT. A phase III clinical trial of 0.5 % levofloxacin ophthalmic solution versus 0.3 % ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003; 110:457‑465.Bertino JS, Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol 2009; 3:507‑521.Bertino JS, Jr. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol 2009; 3:507‑521.Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract 2005; 55:962‑964.Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: Cochrane systematic review and meta-analysis update. Br J Gen Pract 2005; 55:962‑964.Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 2009; 66:587‑604.Sharma PC, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm 2009; 66:587‑604.Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2:378‑424.Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2:378‑424.Nicolau D, Quintiliani R, Nightingale CH. Ofloxacin vs ciprofloxacin: a comparison. Conn Med 1992; 56:261‑263.Nicolau D, Quintiliani R, Nightingale CH. Ofloxacin vs ciprofloxacin: a comparison. Conn Med 1992; 56:261‑263.Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996,23 Suppl 1: S19–24.Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996,23 Suppl 1: S19–24.Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001; 32 Suppl 1: S51–63.Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001; 32 Suppl 1: S51–63.Begg EJ, Barclay ML. Aminoglycosides-–50 years on. Br J Clin Pharmacol 1995; 39:597‑603.Begg EJ, Barclay ML. Aminoglycosides-–50 years on. Br J Clin Pharmacol 1995; 39:597‑603.Bremond-Gignac D, Chiambaretta F, Milazzo S. A European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmol Eye Dis, 2011; 3:29‑43.Bremond-Gignac D, Chiambaretta F, Milazzo S. A European perspective on topical ophthalmic antibiotics: current and evolving options. Ophthalmol Eye Dis, 2011; 3:29‑43.Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996; 37 Suppl:1‑8.Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 1996; 37 Suppl:1‑8.Cochereau I, Meddeb-Ouertani A, Khairallah M, Amraoui A, Zaghloul K, Pop M, et al. 3‑day treatment with azithromycin 1.5 % eye drops versus 7‑day treatment with tobramycin 0.3 % for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007; 91:465‑469.Cochereau I, Meddeb-Ouertani A, Khairallah M, Amraoui A, Zaghloul K, Pop M, et al. 3‑day treatment with azithromycin 1.5 % eye drops versus 7‑day treatment with tobramycin 0.3 % for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children. Br J Ophthalmol 2007; 91:465‑469.Cochereau I, Goldschmidt P, Goepogui A, Afghani T, Delval L, Pouliquen P, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2007; 91:667‑672.Cochereau I, Goldschmidt P, Goepogui A, Afghani T, Delval L, Pouliquen P, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2007; 91:667‑672.Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 safety comparisons for 1.0 % azithromycin in polymeric mucoadhesive eye drops versus 0.3 % tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2007;48:3425‑3429.Protzko E, Bowman L, Abelson M, Shapiro A. Phase 3 safety comparisons for 1.0 % azithromycin in polymeric mucoadhesive eye drops versus 0.3 % tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 2007;48:3425‑3429.EUCAST. Antimicrobial wild type distributions of microorganisms. In; 2014.EUCAST. Antimicrobial wild type distributions of microorganisms. In; 2014.Williams JD. Spectrum of activity of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10:813‑820.Williams JD. Spectrum of activity of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10:813‑820.McIntosh HW, Seraglia M. Clinical Experience with Fusidic Acid. Can Med Assoc J 1963; 89:1245‑1246.McIntosh HW, Seraglia M. Clinical Experience with Fusidic Acid. Can Med Assoc J 1963; 89:1245‑1246.Leclercq R, Bismuth R, Casin I, Cavallo JD, Croize J, Felten A, et al. In vitro activity of fusidic acid against streptococci isolated from skin and soft tissue infections. J Antimicrob Chemother 2000; 45:27‑29.Leclercq R, Bismuth R, Casin I, Cavallo JD, Croize J, Felten A, et al. In vitro activity of fusidic acid against streptococci isolated from skin and soft tissue infections. J Antimicrob Chemother 2000; 45:27‑29.Smadel JE, Leon AP, et al. Chloromycetin in the treatment of patients with typhus fever. Proc Soc Exp Biol Med 1948; 68:12‑19.Smadel JE, Leon AP, et al. Chloromycetin in the treatment of patients with typhus fever. Proc Soc Exp Biol Med 1948; 68:12‑19.Sorsby A, Ungar J, Crick RP. Aureomycin, chloramphenicol, and terramycin in ophthalmology. Br Med J 1953,2:301‑304.Sorsby A, Ungar J, Crick RP. Aureomycin, chloramphenicol, and terramycin in ophthalmology. Br Med J 1953,2:301‑304.Phillips CI. Systematic risks from chloramphenicol eye drops. Br J Gen Pract, 2010; 60:134.Phillips CI. Systematic risks from chloramphenicol eye drops. Br J Gen Pract, 2010; 60:134.Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004; 137:453‑458.Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004; 137:453‑458.Varaldo PE. Antimicrobial resistance and susceptibility testing: an evergreen topic. J Antimicrob Chemother 2002; 50:1‑4.Varaldo PE. Antimicrobial resistance and susceptibility testing: an evergreen topic. J Antimicrob Chemother 2002; 50:1‑4.EUCAST. Breakpoints for topical use of antimicrobial agents: EUCAST Guidance Document In; 2014.EUCAST. Breakpoints for topical use of antimicrobial agents: EUCAST Guidance Document In; 2014.Sharma S. Antibiotic resistance in ocular bacterial pathogens. Indian J Med Microbiol 2011; 29:218‑222.Sharma S. Antibiotic resistance in ocular bacterial pathogens. Indian J Med Microbiol 2011; 29:218‑222.Essa Abdullah F, Irfan Khan M, Waheed S. Current pattern of antibiotic resistance of clinical isolates among conjunctival swabs. Pak J Med Sci; 2013; 29:81‑84.Essa Abdullah F, Irfan Khan M, Waheed S. Current pattern of antibiotic resistance of clinical isolates among conjunctival swabs. Pak J Med Sci; 2013; 29:81‑84.Orlans HO, Hornby SJ, Bowler IC. In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10‑year review. Eye (Lond), 2011; 25:489‑493.Orlans HO, Hornby SJ, Bowler IC. In vitro antibiotic susceptibility patterns of bacterial keratitis isolates in Oxford, UK: a 10‑year review. Eye (Lond), 2011; 25:489‑493.Zhang C , Liang Y, Deng S, Wang Z , Li R, Sun X. Distribution of bacterial keratitis and emerging resistance to antibiotics in China from 2001 to 2004. Clin Ophthalmol 2008; 2:575‑579.Zhang C , Liang Y, Deng S, Wang Z , Li R, Sun X. Distribution of bacterial keratitis and emerging resistance to antibiotics in China from 2001 to 2004. Clin Ophthalmol 2008; 2:575‑579.Graves A, Henry M, O’Brien TP, Hwang DG, Van Buskirk A, Trousdale MD. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea 2001; 20:301‑305.Graves A, Henry M, O’Brien TP, Hwang DG, Van Buskirk A, Trousdale MD. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Cornea 2001; 20:301‑305.Miller D, Alfonso EC. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. Cornea 2004; 23:289‑293.Miller D, Alfonso EC. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. Cornea 2004; 23:289‑293.Egger SF, Ruckhofer J, Alzner E, Hell M, Hitzl W, Huber-Spitzy V, Grabner G. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res 2001; 33:117‑120.Egger SF, Ruckhofer J, Alzner E, Hell M, Hitzl W, Huber-Spitzy V, Grabner G. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res 2001; 33:117‑120.Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008; 145:951‑958.Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008; 145:951‑958.Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001 / 2002. J Infect 2004; 49:109‑114.Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001 / 2002. J Infect 2004; 49:109‑114.Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol 2007; 55:15‑19.Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol 2007; 55:15‑19.T. N. Vorontsova, V. V. Brzheskii, E. L. Efimova, L. P. Prozornaya, M. V. Mikhailova, Krepkikh EM. [Microflora of a conjunctival cavity and its sensitivity to antibacterial preparations at children in normal and at some inflammatory diseases ofT. N. Vorontsova, V. V. Brzheskii, E. L. Efimova, L. P. Prozornaya, M. V. Mikhailova, Krepkikh EM. [Microflora of a conjunctival cavity and its sensitivity to antibacterial preparations at children in normal and at some inflammatory diseases ofeyes]. Oftal’mologicheskie vedomosti. [Ophthalmologic sheets]. 2010; 2:61‑65. (in Russ.).eyes]. Oftal’mologicheskie vedomosti. [Ophthalmologic sheets]. 2010; 2:61‑65. (in Russ.).Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, Bloom A. Penetration of topically applied gatifloxacin 0.3 %, moxifloxacin 0.5 %, and ciprofloxacin 0.3 % into the aqueous humor. Ophthalmology 2005;112:466‑469.Solomon R, Donnenfeld ED, Perry HD, Snyder RW, Nedrud C, Stein J, Bloom A. Penetration of topically applied gatifloxacin 0.3 %, moxifloxacin 0.5 %, and ciprofloxacin 0.3 % into the aqueous humor. Ophthalmology 2005;112:466‑469.Koch HR, Kulus SC, Roessler M, Ropo A, Geldsetzer K. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5 % and ofloxacin 0.3 % eyedrops. J Cataract Refract Surg 2005;Koch HR, Kulus SC, Roessler M, Ropo A, Geldsetzer K. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5 % and ofloxacin 0.3 % eyedrops. J Cataract Refract Surg 2005;:1377‑1385.:1377‑1385.Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007; 144:315‑318.Lai WW, Chu KO, Chan KP, Choy KW, Wang CC, Tsang CW, Pang CP. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol 2007; 144:315‑318.Holland EJ, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5 % and gatifloxacin 0.3 % ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin 2007; 23:2955‑2960.Holland EJ, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5 % and gatifloxacin 0.3 % ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin 2007; 23:2955‑2960.Leeming JP, Diamond JP, Trigg R, White L, Hoh HB, Easty DL. Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora. Br J Ophthalmol 1994; 78:546‑548.Leeming JP, Diamond JP, Trigg R, White L, Hoh HB, Easty DL. Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora. Br J Ophthalmol 1994; 78:546‑548.Diamond JP, White L, Leeming JP, Bing Hoh H, Easty DL. Topical 0.3 % ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol 1995;79:606‑609.Diamond JP, White L, Leeming JP, Bing Hoh H, Easty DL. Topical 0.3 % ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. Br J Ophthalmol 1995;79:606‑609.Cagini C, Piccinelli F, Lupidi M, Messina M, Cerqualglia A, Manes S, et al. Ocular penetration of topical antibiotics: study on the penetration of chloramphenicol, tobramycin and netilmicin into the anterior chamber after topical administration.Cagini C, Piccinelli F, Lupidi M, Messina M, Cerqualglia A, Manes S, et al. Ocular penetration of topical antibiotics: study on the penetration of chloramphenicol, tobramycin and netilmicin into the anterior chamber after topical administration.Clin Experiment Ophthalmol, 2013; 41:644‑647.Clin Experiment Ophthalmol, 2013; 41:644‑647.Torkildsen G, O’Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1 % and moxifloxacin 0.5 % ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. ClinTorkildsen G, O’Brien TP. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1 % and moxifloxacin 0.5 % ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers. ClinTher 2008; 30:2005‑2014.Ther 2008; 30:2005‑2014.Fraunfelder FT, Bagby GC, Jr., Kelly DJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93:356‑360.Fraunfelder FT, Bagby GC, Jr., Kelly DJ. Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol. Am J Ophthalmol 1982; 93:356‑360.McWhae JA, Chang J, Lipton JH. Drug-induced fatal aplastic anemia following cataract surgery. Can J Ophthalmol 1992; 27:313‑315.McWhae JA, Chang J, Lipton JH. Drug-induced fatal aplastic anemia following cataract surgery. Can J Ophthalmol 1992; 27:313‑315.Eedy DJ, McMillan JC, Bingham EA. Anaphylactic reactions to topical antibiotic combinations. Postgrad Med J 1990; 66:858‑859.Eedy DJ, McMillan JC, Bingham EA. Anaphylactic reactions to topical antibiotic combinations. Postgrad Med J 1990; 66:858‑859.Tsai TH, Chen WL, Hu FR. Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells. Eye (Lond) 2010; 24:909‑917.Tsai TH, Chen WL, Hu FR. Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells. Eye (Lond) 2010; 24:909‑917.Ayaki M, Iwasawa A, Niwano Y. In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. Biocontrol Sci,2012; 17:93‑99.Ayaki M, Iwasawa A, Niwano Y. In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines. Biocontrol Sci,2012; 17:93‑99.

The authors declare that there are no conflicts of interest present.